U.S. stocks were lower, with the Dow Jones index falling around 450 points on Tuesday.
Shares of Roivant Sciences Ltd (NASDAQ:ROIV) rose sharply during Tuesday’s session after the company shared topline data from its Phase 2 PHocus clinical trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Presented at the European Respiratory Society International Congress 2026, the data highlight meaningful clinical progress in PH-ILD patients.
Roivant Sciences shares jumped 16.3% to $40.62 on Tuesday.
Here are some other big stocks recording gains in today’s session.
Photo via Shutterstock